These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35287261)

  • 41. In-Home Remote Assessment of the MDS-UPDRS Part III: Multi-Cultural Development and Validation of a Guide for Patients.
    Tosin MHS; Sanchez-Ferro A; Wu RM; de Oliveira BGRB; Leite MAA; Suárez PR; Goetz CG; Martinez-Martin P; Stebbins GT; Mestre TA
    Mov Disord Clin Pract; 2024 Sep; ():. PubMed ID: 39310988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST.
    Watanabe H; Saiki H; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Maeda T; Shimo Y;
    Mov Disord Clin Pract; 2020 May; 7(4):431-439. PubMed ID: 32373660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease.
    Cova I; Di Battista ME; Vanacore N; Papi CP; Alampi G; Rubino A; Valente M; Meco G; Contri P; Di Pucchio A; Lacorte E; Priori A; Mariani C; Pomati S
    Parkinsonism Relat Disord; 2017 Jan; 34():38-42. PubMed ID: 28029554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
    Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
    Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
    Skorvanek M; Martinez-Martin P; Kovacs N; Rodriguez-Violante M; Corvol JC; Taba P; Seppi K; Levin O; Schrag A; Foltynie T; Alvarez-Sanchez M; Arakaki T; Aschermann Z; Aviles-Olmos I; Benchetrit E; Benoit C; Bergareche-Yarza A; Cervantes-Arriaga A; Chade A; Cormier F; Datieva V; Gallagher DA; Garretto N; Gdovinova Z; Gershanik O; Grofik M; Han V; Huang J; Kadastik-Eerme L; Kurtis MM; Mangone G; Martinez-Castrillo JC; Mendoza-Rodriguez A; Minar M; Moore HP; Muldmaa M; Mueller C; Pinter B; Poewe W; Rallmann K; Reiter E; Rodriguez-Blazquez C; Singer C; Tilley BC; Valkovic P; Goetz CG; Stebbins GT
    Mov Disord Clin Pract; 2017; 4(4):536-544. PubMed ID: 30363418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.
    Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
    Mov Disord; 2003 Jul; 18(7):738-50. PubMed ID: 12815652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. German translation and validation of the "freezing of gait questionnaire" in patients with Parkinson's disease.
    Vogler A; Janssens J; Nyffeler T; Bohlhalter S; Vanbellingen T
    Parkinsons Dis; 2015; 2015():982058. PubMed ID: 25705546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does MDS-UPDRS Provide Greater Sensitivity to Mild Disease than UPDRS in De Novo Parkinson's Disease?
    Tosin MHS; Stebbins GT; Comella C; Patterson CG; Hall DA;
    Mov Disord Clin Pract; 2021 Oct; 8(7):1092-1099. PubMed ID: 34631945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of Smartphone-Based Testing of Interference in Parkinson's Disease.
    Lee W; Williams DR; Evans A
    Neurodegener Dis; 2018; 18(2-3):133-142. PubMed ID: 29940579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship of Movement Disorders Society-Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease.
    Bernard BA; Carns D; Stebbins GT; Goldman JG; Goetz CG
    Mov Disord Clin Pract; 2020 Apr; 7(3):279-283. PubMed ID: 32258225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
    Pahwa R; Fox S; Hauser RA; Isaacson S; Lytle J; Johnson R; Llorens L; Formella AE; Tanner CM
    Front Neurol; 2022; 13():846126. PubMed ID: 36341088
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.
    Holiday KA; Pirogovsky-Turk E; Malcarne VL; Filoteo JV; Litvan I; Lessig SL; Song D; Schiehser DM
    Mov Disord Clin Pract; 2017; 4(5):717-723. PubMed ID: 28435846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson's disease.
    Raciti L; Nicoletti A; Mostile G; Bonomo R; Dibilio V; Donzuso G; Sciacca G; Cicero CE; Luca A; Zappia M
    Neurol Sci; 2019 Jun; 40(6):1271-1273. PubMed ID: 30737581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of the Parkinson's KinetiGraph and clinical assessment in the management of Parkinson's disease.
    Chaudhuri KR; Hand A; Obam F; Belsey J
    J Med Econ; 2022; 25(1):774-782. PubMed ID: 35593687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson's disease.
    Jafari N; Pahwa R; Nazzaro JM; Arnold PM; Lyons KE
    Int J Neurosci; 2016; 126(1):25-9. PubMed ID: 26134878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation Between the Movement Disorder Society's Unified Parkinson's Disease Rating Scale and Nonmotor Scales in Patients with Parkinson's Disease.
    Driver-Dunckley ED; Zhang N; Shill HA; Mehta SH; Belden CM; Zamrini EY; Davis K; Beach TG; Adler CH
    Innov Clin Neurosci; 2019 Sep; 16(9-10):27-29. PubMed ID: 32082946
    [No Abstract]   [Full Text] [Related]  

  • 57. Objective assessment of bradykinesia in Parkinson's disease using evolutionary algorithms: clinical validation.
    Gao C; Smith S; Lones M; Jamieson S; Alty J; Cosgrove J; Zhang P; Liu J; Chen Y; Du J; Cui S; Zhou H; Chen S
    Transl Neurodegener; 2018; 7():18. PubMed ID: 30147869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
    Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
    J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.
    Rodriguez-Blazquez C; Rojo-Abuin JM; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG; Martinez-Martin P
    Parkinsonism Relat Disord; 2013 Oct; 19(10):889-93. PubMed ID: 23791519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Parkinson's Disease Composite Scale: results of the first validation study.
    Stocchi F; Radicati FG; Chaudhuri KR; Johansson A; Padmakumar C; Falup-Pecurariu C; Martinez-Martin P
    Eur J Neurol; 2018 Mar; 25(3):503-511. PubMed ID: 29193455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.